NDAORALTABLET
Approved
Feb 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
4/8 — Partial
ALLEGRA HIVES (fexofenadine hydrochloride) by Sanofi. Approved for hives, relieves itching due to hives (urticaria), an allergic skin reaction from occurring. First approved in 2000.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALLEGRA HIVES (fexofenadine hydrochloride) is an oral antihistamine tablet approved in 2000 for the treatment of hives (urticaria) and relief of itching associated with allergic skin reactions. It is a non-sedating H1-receptor antagonist that works by blocking histamine-mediated allergic responses. The drug prevents and alleviates the symptoms of urticaria through peripheral histamine receptor blockade.
LOE Approaching
As LOE approaches, the brand team is likely consolidating and focusing on defensive strategies; significant headcount reductions are typical in this phase.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on ALLEGRA HIVES at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.